Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 566 of 5804
-
A smartphone app may ease fibromyalgia — a 360-person trial investigates
Symptom relief Recruiting nowIntroduction: Fibromyalgia (FM) is a prevalent syndrome that lacks curative treatment, imposing high healthcare and societal costs. The SMART-FM-Spain study investigates the effectiveness, physiological effects, and cost-utility of a self-guided digital intervention (STANZA-Spain…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Immunotherapy before surgery may help remove stubborn colon cancer
Disease control OngoingDue to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adj…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for rare leukemia: Anthracycline-Free combo trial launches
Disease control Recruiting nowThis investigator-initiated, single-arm, phase II trial is aimed to evaluate the efficacy and safety of a venetoclax-based, anthracycline-free regimen in patients with newly diagnosed CBFβ::MYH11-positive acute myeloid leukemia.
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
New hope for VHL patients: belzutifan trial targets rare tumor disorder
Disease control Recruiting nowThe BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.
Phase: PHASE2 • Sponsor: José Claudio Casali da Rocha • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC
-
Sound waves vs. seizures: new ultrasound trial for Hard-to-Treat epilepsy
Disease control Recruiting nowFocused ultrasound (FUS) has been shown to differentially lesion or modulate (excite and inhibit) brain circuit and neural activity across a broad range of acoustic stimulus parameters (intensity, duty cycle, pulse repetition frequency and pulse duration) for decades. From our pr…
Phase: NA • Sponsor: Taipei Veterans General Hospital, Taiwan • Aim: Disease control
Last updated Jun 26, 2026 14:30 UTC
-
New heart valve clip could spare patients from Open-Heart surgery
Disease control Recruiting nowTo confirm the effectiveness and safety of the DragonFly Transcatheter Mitral Valve Repair System for the treatment of symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation in high surgical risk subjects and symptomatic moderate-to- severe (3+) or s…
Phase: NA • Sponsor: Hangzhou Valgen Medtech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Exercise program aims to protect hearts of young cancer survivors
Disease control Recruiting nowPediatric, adolescent and young adult cancer survivors (PAYA-CS) are at higher risk of cardiovascular (CV) morbidity and mortality. This is a consequence of prior cancer-related therapies that have the potential of producing cardiac dysfunction, reducing cardiorespiratory fitness…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could two old drugs free thalassemia patients from lifelong transfusions?
Disease control CompletedBeta thalassemia Major (BTM) is the most common hemoglobinopathy caused by mutations in the beta-globin gene . Worldwide, approximately 80 million people carry thalassemia gene mutation. Around 23,000 babies are affected by BTM each year, of which around 90% belong to low- or mid…
Phase: PHASE2 • Sponsor: Pakistan Blood and Marrow Transplant (PBMT) Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control ENROLLING_BY_INVITATIONThis study will determine the safe initial injected activity of the radioligand therapy 177Lu-HTK03170 for the measurement of dosimetry and initiation of treatment in subjects with PSMA-positive, metastatic castrate resistant prostate cancer, (mCRPC). Subjects will receive treatm…
Phase: PHASE1, PHASE2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Surgery + diabetes drug: a new One-Two punch against severe obesity?
Disease control Recruiting nowObese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deteriorati…
Phase: PHASE1, PHASE2 • Sponsor: China-Japan Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on advanced cancers in early trial
Disease control Recruiting now1. Study Title: Efficacy and safety of MSLN CAR-T in advanced malignant tumors 2. Study Objectives: Primary: To evaluate the safety and tolerability of MSLN-targeted CAR-T cell therapy in patients with stage III/IV advanced malignant tumors. Secondary: To preliminaril…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo shows promise for rare childhood leukemia
Disease control OngoingThis is a prospective, single-arm, open-label clinical study to evaluate the efficacy and safety of Selinexor combined with a standardized induction chemotherapy regimen (ZJCH-AML) for children with NUP98-fusion positive Acute Myeloid Leukemia (AML). NUP98-fusion positive AML is…
Phase: PHASE2 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Blood test could spot colon cancer before it spreads
Diagnosis Recruiting nowThis is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the …
Sponsor: San Raffaele University • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
AI reads scans and slides to outsmart stomach cancer
Diagnosis CompletedBackground: Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Accurate pre-operative diagnosis, risk stratification, and genotyping are critical for determining the appropriate surgical approach and targeted therapy (suc…
Sponsor: Qun Zhao • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New combo aims to tackle Hard-to-Treat breast cancer
Disease control Recruiting nowThis is a multicenter, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of disitamab vedotin in combination with bevacizumab in patients with HER2-low advanced or metastatic breast cancer who have experienced disease progression following prior T-D…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Sound waves vs. OCD: new hope for tough cases?
Symptom relief ENROLLING_BY_INVITATIONThe goal of this clinical trial is to evaluate If magnetic resonance-guided focused ultrasound works to treat refractory obsessive-compulsive disorder in adults. The main questions it aims to answer are: * What effectiveness does the magnetic resonance-guided focused ultrasound …
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
New antibody shows promise for tough thyroid eye disease
Disease control CompletedThis is an exploratory study of the efficacy and safety of IBI311, a modified anti-IGF-1R antibody, in patients with steroid-resistant, thyroid associated ophthalmopathy (TAO). This study includes two stages. Stage I is a single-center, single-arm, open-label clinical study desig…
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cocktail targets lung cancer in the brain: triple therapy shows promise in early trial
Disease control Completedthe study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy may help rectal cancer patients avoid surgery
Disease control Recruiting nowThis is an open-label, multi-center, single-arm clinical study. All patients received 4-6 cycles total neoadjuvant therapy plus concurrent tislelizumab immunotherapy, then underwent clinical response assessment. Patients who achieved CR (cCR+ pCR confirmed by local resection of n…
Phase: PHASE1, PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for tough prostate cancer: experimental drug takes on standard treatments
Disease control Recruiting nowThis is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously trea…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC